Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 15Thoracic 6Breast 3Sarcoma 2Gynecologic 2Plasma cell 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 166Triple Negative Breast Neoplasms 54Neoplasm Metastasis 23Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 11Colorectal Neoplasms 9Small Cell Lung Carcinoma 8Sarcoma 8Neoplasms 8Lung Neoplasms 8Prostatic Neoplasms 7Colonic Neoplasms 7Breast Neoplasms, Male 7Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Recurrence 3Rectal Neoplasms 3Multiple Myeloma 3Melanoma 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2

Interventions

Early Intervention, Educational 5Radiotherapy 4Psychiatric Rehabilitation 4Capecitabine 4pembrolizumab 3Trastuzumab 3Methods 3Magnetic Resonance Spectroscopy 3Irinotecan 3Gemcitabine 3Counseling 3trametinib 2palbociclib 2cediranib 2Standard of Care 2Mental Status and Dementia Tests 2Fluorodeoxyglucose F18 2Docetaxel 2Cyclophosphamide 2Biopsy 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2veliparib 1ulixertinib 1trastuzumab biosimilar HLX02 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1relatlimab 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Rectal Neoplasms × Gemcitabine × Breast × Clear all
NCT02632448 2025-05-02

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Esperas Pharma Inc.

Phase 1/2 Completed
229 enrolled
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Triple Negative Breast Neoplasms

NCT00004095 2017-04-18

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

Northwestern University

Phase 1 Completed
38 enrolled
BreastGastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT00049608 2013-06-19

Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
51 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡